Iterative Health vs Ultromics EchoGo
SKOUT has a randomized trial behind it. In the 2022 Gastroenterology randomized trial, 22 endoscopists at five centers recorded 0.83 adenomas per colonoscopy with standard colonoscopy in 677 patients and 1.05 with CADe in 682 (P=.002). Adenoma detection rate went from 43.9% to 47.8% (P=.065, not significant), and the trial was sponsor-run by the company's registration study team. openFDA lists six SKOUT decisions from August 12, 2022 to December 22, 2025. The company's home page now leads with clinical research for providers and sponsors.
Ultromics goes to cardiology. EchoGo Amyloidosis screens adults 65 and older with heart failure and was cleared November 15, 2024 under K240860, with EchoGo Heart Failure as predicate.
Endoscopists and endoscopy centers buy SKOUT for colonoscopy, echo labs buy EchoGo for transthoracic studies, and a GI group with a cardiology line would be funding two unrelated tools.
Radiology · Reviewed November 2, 2026
Iterative Health
by Iterative Health · founded 2017
Real-time AI polyp detection for colonoscopy with the FDA-cleared SKOUT system, for endoscopists and endoscopy centers.
Ultromics EchoGo
by Ultromics
FDA-cleared AI on echocardiograms that flags heart failure with preserved ejection fraction and screens for cardiac amyloidosis.
When to pick each one
Iterative Health
- Randomized trial of SKOUT, 1,359 patients
- Adenomas per colonoscopy 1.05 versus 0.83
- Six openFDA decisions, August 2022 to December 2025
Ultromics EchoGo
- Amyloidosis screening aid for adults 65 and older
- Cleared November 15, 2024 under K240860
Score
Each row shows points earned of points available under the published rubric.
Iterative Health
42of 100
Ultromics EchoGo
42of 100
| Dimension | Iterative Health | Ultromics EchoGo | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 6 / 10 | -6 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 0 / 18.2 | 0 / 18.2 | 0 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
Iterative Health
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Demo request only. |
Ultromics EchoGo
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
Iterative Health
FDA decisions
K253664 (opens in new tab)510(k)2025-12-22
SKOUT system
K251126 (opens in new tab)510(k)2025-05-09
SKOUT system
K241508 (opens in new tab)510(k)2024-07-03
SKOUT system
K240781 (opens in new tab)510(k)2024-04-19
SKOUT system
K230658 (opens in new tab)510(k)2023-04-07
SKOUT system
Show 1 more
K213686 (opens in new tab)510(k)2022-08-12
SKOUT Software
Ultromics EchoGo
FDA decisions
K240860 (opens in new tab)510(k)2024-11-15
EchoGo Amyloidosis (1.0)
K240013 (opens in new tab)510(k)2024-09-23
EchoGo Heart Failure (2.0)
K222463 (opens in new tab)510(k)2022-11-23
EchoGo Heart Failure 1.0
K213275 (opens in new tab)510(k)2021-12-20
EchoGo Core (2.0)
K201555 (opens in new tab)510(k)2020-12-18
EchoGo Pro v1.0.2
Show 1 more
K191171 (opens in new tab)510(k)2019-11-13
EchoGo Core
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Iterative Health | Ultromics EchoGo |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2017 | n/a |
| HQ | US | GB |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.